ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
For all media inquiries, please contact media@tempus.com
  • 04/24/2025

    Tempus to Report First Quarter 2025 Financial Results on May 6

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.Â...

  • 04/23/2025

    Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced  multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can b...

  • 04/18/2025

    Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the...

  • 04/15/2025

    Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation

    Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease

    Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI...

  • 03/29/2025

    Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presentin...

  • 03/26/2025

    Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025. Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the...

  • 03/11/2025

    Tempus Announces Acquisition of Deep 6 AI

    Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI enables healthcare organizations to de-risk clinical...

  • 02/24/2025

    Tempus Reports Fourth Quarter and Full Year 2024 Results

    CHICAGO, February 24, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. Revenue growth accelerated to 35.8% year-over-year in the fourth quarter of 2024 Gross profit growth accelerated to 49.7% in...

  • 02/21/2025

    Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer

    Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help clinicians support more informed treatment-making decisions. The Next platform will analyze clinical data from mBC...

  • 02/19/2025

    Tempus to Present at TD Cowen’s 45th Annual Health Care Conference

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA. Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23